AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

  • Byung Hyun Cha (Creator)
  • Minjin Jung (Creator)
  • Angela S. Kim (Creator)
  • Victoria C. Lepak (Creator)
  • Brett Colson (Creator)
  • David A Bull (Creator)
  • Youngwook Won (Creator)
  • Byung Hyun Cha (Creator)



Abstract Cardiac hypertrophy is one of the most common genetic heart disorders and considered a risk factor for cardiac morbidity and mortality. The mammalian target of rapamycin (mTOR) pathway plays a key regulatory function in cardiovascular physiology and pathology in hypertrophy. AZD2014 is a small-molecule ATP competitive mTOR inhibitor working on both mTORC1 and mTORC2 complexes. Little is known about the therapeutic effects of AZD2014 in cardiac hypertrophy and its underlying mechanism. Here, AZD2014 is examined in in vitro model of phenylephrine (PE)-induced human cardiomyocyte hypertrophy and a myosin-binding protein-C (Mybpc3)-targeted knockout (KO) mouse model of cardiac hypertrophy. Our results demonstrate that cardiomyocytes treated with AZD2014 retain the normal phenotype and AZD2014 attenuates cardiac hypertrophy in the Mybpc3-KO mouse model through inhibition of dual mTORC1 and mTORC2, which in turn results in the down-regulation of the Akt/mTOR signaling pathway.
Date made available2021

Cite this